<DOC>
	<DOCNO>NCT00287716</DOCNO>
	<brief_summary>The objective study assess safety efficacy treatment pirfenidone 2403 milligram per day ( mg/d ) compare placebo patient idiopathic pulmonary fibrosis ( IPF ) , assess safety efficacy treatment pirfenidone 1197 mg/d patient idiopathic pulmonary fibrosis characterize pharmacokinetic disposition pirfenidone patient idiopathic pulmonary fibrosis .</brief_summary>
	<brief_title>Three-Arm Study Safety Efficacy Pirfenidone Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>This Phase 3 , randomize , double blind , placebo-controlled , three-arm , safety efficacy study pirfenidone patient idiopathic pulmonary fibrosis . Approximately 400 patient approximately 70 center randomly assign ( 2:2:1 ) receive either 2403 milligram ( mg ) pirfenidone , placebo equivalent , 1197 mg pirfenidone administer divided dos three time per day ( TID ) food . Patients randomize geographic region . Patients receive blind study treatment time randomization last patient randomize treated 72 week . A Data Monitoring Committee ( DMC ) periodically review safety efficacy data ensure patient safety . After week 72 , patient meet Progression Disease ( POD ) definition , ≥ 10 % absolute decrease percent predict FVC ≥ 15 % absolute decrease percent predict carbon monoxide diffuse capacity ( DLco ) , eligible receive permit IPF therapy addition blind study drug . Permitted IPF therapy include corticosteroid , azathioprine , cyclophosphamide N-acetyl-cysteine ( restriction ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Primary Inclusion criterion : diagnosis idiopathic pulmonary fibrosis 40 80 year age Forced Vital Capacity great equal 50 % predict value Carbon monoxide diffuse capacity great equal 35 % predict value either Forced Vital Capacity Carbon monoxide diffuse capacity less equal 90 % predict value improvement past year able walk 150 meter 6 minute maintain saturation great equal 83 % 6 liter per minute ( L/min ) supplemental oxygen Primary Exclusion criterion : unable undergo pulmonary function test evidence significant obstructive lung disease airway hyperresponsiveness opinion investigator patient expect need eligible lung transplant within 72 week randomization active infection liver disease cancer medical condition likely result death within 2 year diabetes pregnancy lactation substance abuse personal family history long QT ( Q wave , T wave ) syndrome IPF treatment unable take study medication withdrawal IPF trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Idiopathic</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Lung</keyword>
	<keyword>Pirfenidone</keyword>
	<keyword>InterMune</keyword>
</DOC>